News

Targeted Oncology1h
AMPLITUDE Trial: What Community Oncologists Should Know
Discover the groundbreaking AMPLITUDE trial results, showcasing niraparib's effectiveness in treating metastatic prostate cancer with minimal safety concerns.
Targeted Oncology3h
OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology5h
FDA Grants Priority Review for Lurbinectedin/Atezolizumab in ES-SCLC
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology22h
Bridging and BCMA Exposure Impact Ide-Cel Outcomes in Multiple Myeloma
During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...
Targeted Oncology23h
Digital App Improves Caregiver Well-Being Post HSCT
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.